Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Post-Mkt 03-02 18:46:58 EST

42.55

-0.68

-1.57%

盘后42.55

+0.000.00%

17:58 EST

High44.00	Low42.26	Vol1.33M
Open42.57	D1 Closing43.23	Amplitude4.03%
Mkt Cap3.54B	Tradable Cap3.31B	Total Shares83.19M
T/O57.04M	T/O Rate1.71%	Tradable Shares77.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":42.55,"timestamp":1772485200000,"preClose":43.23,"halted":0,"volume":1326808,"hourTrading":{"tag":"盘后","latestPrice":42.55,"preClose":42.55,"latestTime":"17:58 EST","volume":54600,"amount":2323228.362,"timestamp":1772492311618,"change":0,"changeRate":0,"amplitude":0.000705},"delay":0,"changeRate":-0.015729817256534807,"floatShares":77681000,"shares":83190316,"eps":-4.364588,"marketStatus":"Post-Mkt","change":-0.68,"latestTime":"03-02 18:46:58 EST","open":42.57,"high":44,"low":42.26,"amount":57040490.92812,"amplitude":0.04025,"askPrice":43.38,"askSize":46,"bidPrice":42.55,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-4.364588,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772499600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":43.23,"preHourTrading":{"tag":"盘前","latestPrice":43.06,"preClose":43.23,"latestTime":"09:28 EST","volume":19773,"amount":850223.1816,"timestamp":1772461680055,"change":-0.17,"changeRate":-0.003932,"amplitude":0.164932},"postHourTrading":{"tag":"盘后","latestPrice":42.55,"preClose":42.55,"latestTime":"17:58 EST","volume":54600,"amount":2323228.362,"timestamp":1772492311618,"change":0,"changeRate":0,"amplitude":0.000705},"volumeRatio":1.406581,"impliedVol":1.6094,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/XENE/wiki","defaultTab":"wiki","newsList":[{"id":"2616366821","title":"A Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2616366821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616366821?lang=en_us&edition=fundamental","pubTime":"2026-03-01 17:16","pubTimestamp":1772356572,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares.\nSee our latest analysis for Xenon Pharmaceuticals.\nThe US$43.23 share price has seen a mixed stretch, with a 5.41% 1 month share price return and a 2.37% 7 day gain, but a modest year to date decline and recent pressure following the wider losses and US$400 million at the market offering...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-wider-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2614089991","title":"Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089991","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089991?lang=en_us&edition=fundamental","pubTime":"2026-02-28 09:38","pubTimestamp":1772242702,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE","BK4139","BK4112","BLSX","BLSG"],"gpt_icon":0},{"id":"2614386096","title":"Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2614386096","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614386096?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:45","pubTimestamp":1772228731,"startTime":"0","endTime":"0","summary":"The latest update is out from Xenon ( ($XENE) ). On February 27, 2026, Xenon Pharmaceuticals Inc. filed a prospectus supplement with the U.S. Secur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-refreshes-400-million-atm-equity-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-refreshes-400-million-atm-equity-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","EQR","BK4139","BK4585","XENE","BK4588"],"gpt_icon":0},{"id":"2614654848","title":"Analysts Conflicted on These Healthcare Names: Xenon (XENE), Idexx Laboratories (IDXX) and Warby Parker (WRBY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614654848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614654848?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:10","pubTimestamp":1772212210,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xenon (XENE – Research Report), Idexx Laboratories (IDXX – Resear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-xenon-xene-idexx-laboratories-idxx-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-xenon-xene-idexx-laboratories-idxx-and-warby-parker-wrby-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WRBY","XENE","LU1291159041.SGD","LU1941712264.USD","LU2404859667.USD","XBI","HCSG","BK4588","GB00B4QBRK32.GBP","BK4137","BK4581","LU0690374961.EUR","LU1989771016.USD","LU0345774631.USD","GB00B4LPDJ14.GBP","LU0029874061.USD","LU0690374615.EUR","BK4585","XLV","LU0170899867.USD","LABU","BK4139","LU0128526141.USD","LU1941712348.USD","BK4200","IDXX","LU2404859741.USD","BK4082","BK4504","LU0345774391.USD","BK4567"],"gpt_icon":0},{"id":"2614863119","title":"Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2614863119","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614863119?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:40","pubTimestamp":1772210400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 11:40 ET (16:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2614868266","title":"RBC Capital Adjusts Xenon Pharmaceuticals PT to $59 From $58, Maintains Outperform - Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614868266","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614868266?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:59","pubTimestamp":1772207957,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of Buy and mean price target of $56.42, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"gpt_icon":0},{"id":"2614076074","title":"Xenon Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614076074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614076074?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:17","pubTimestamp":1772144259,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings SummaryXenon Pharmaceuticals Inc XENE.OQ reported a quarterly adjusted loss of $1.15 per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM3HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2614207902","title":"Xenon Pharmaceuticals Q4 EPS $(1.31) Misses $(1.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614207902","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614207902?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:34","pubTimestamp":1772141699,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Q4 EPS $(1.31) Misses $(1.19) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50912811/xenon-pharmaceuticals-q4-eps-1-31-misses-1-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals Q4 EPS $(1.31) Misses $(1.19) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2614079770","title":"Canada's Xenon Pharma reports bigger-than-expected net loss in Q4 due to high R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079770","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079770?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:33","pubTimestamp":1772141604,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma reports bigger-than-expected net loss in Q4 due to high R&D expensesOverviewCanada-based biopharma's Q4 net income was $105.3 millionNet loss for Q4 increased due to higher R&D e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM1G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2614075648","title":"Xenon posts FY 2025 net loss of USD 345.9 million (47.6%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075648","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075648?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:02","pubTimestamp":1772139728,"startTime":"0","endTime":"0","summary":"Xenon posts FY 2025 net loss of USD 345.9 million (47.6%)               Xenon reported a Q4 net loss of USD 105.3 million and a FY 2025 net loss of USD 345.9 million. Q4 R&D expenses were USD 87.7 mil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLqS1b0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","XENE","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2614007563","title":"BRIEF-Xenon Pharmaceuticals Q4 Net Income USD -105.261 Million Vs. IBES Estimate USD -95.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007563","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007563?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139709,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q4 Net Income USD -105.261 Million Vs. IBES Estimate USD -95.9 Million\n\n\nFeb 26 (Reuters) - Xenon Pharmaceuticals Q4 income from operations USD -109.767 million.\n\nQ4 operating expenses USD 109.767 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX58F5A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2614756830","title":"Xenon Pharmaceuticals options imply 24.8% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2614756830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614756830?lang=en_us&edition=fundamental","pubTime":"2026-02-27 04:45","pubTimestamp":1772138757,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Xenon Pharmaceuticals (XENE) is normal with calls leading puts 14:1. Implied volatility suggests the market is antic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-options-imply-24-8-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-options-imply-24-8-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2613471952","title":"Xenon Pharmaceuticals Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2613471952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613471952?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:34","pubTimestamp":1771936440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 07:34 ET (12:34 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2604511801","title":"Xenon (XENE) Receives a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2604511801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604511801?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:36","pubTimestamp":1768912591,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero maintained a Buy rating on Xenon today and set a price target of $62.00. Romero covers the Healthcare sector, focu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-j-p-morgan-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xenon-xene-receives-a-buy-from-j-p-morgan-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051017.SGD","LU1244550494.USD","LU1732800096.USD","BK4504","XENE","BK4585","IE00BKVL7J92.USD","LU1074936037.SGD","LU0314104364.USD","LU0528227936.USD","LU2111349929.HKD","LU0225283273.USD","LU0795875086.SGD","LU0795875169.SGD","LU1720051108.HKD","LU0158827781.USD","LU2271345857.HKD","LU2028103732.USD","LU0882574139.USD","LABU","LU1244550577.SGD","BK4534","BK4127","LU1791710400.SGD","LU0106261372.USD","LU1363072403.SGD","LU2089284900.SGD","LU2133065610.SGD","LU0267386448.USD","LU0106831901.USD","LU1162221912.USD","LU0098860793.USD","LU1668664300.SGD","LU2089283258.USD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1989772923.USD","BK4588","LU0158827948.USD","LU2347655156.SGD","LU2023251221.USD","LU0557290698.USD","BK4581","BK4516","XBI","LU1989772840.SGD","XLV","LU0006306889.USD","BK4139"],"gpt_icon":0},{"id":"2604919695","title":"Xenon Pharmaceuticals Grants Equity Inducement Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919695?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:05","pubTimestamp":1768597522,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. has granted equity inducement awards to ten new non-officer employees, totaling 42,300 share options. The options have an exercise price of $40.74 per common share, reflecting the closing price on January 15, 2026. These share options vest over four years, with 25% vesting on the one-year anniversary of each employee's start date and the remainder vesting monthly over the following three years. Each option carries a 10-year term and is subject to the terms of the company’s Amended and Restated 2025 Inducement Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3rgKZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","XENE","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2604919616","title":"Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919616","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919616?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:05","pubTimestamp":1768597500,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2404859667.USD","LU1046421795.USD","LU0157215616.USD","LU2125154935.USD","IE00B19Z8W00.USD","LU2461242641.AUD","LU0006306889.USD","LU0690374961.EUR","XENE","LU0690374615.EUR","LU0861579265.USD","LU2125154778.USD","LU0354030511.USD","LU1116320737.USD","IE00BKVL7J92.USD","LU1712237335.SGD","LU0158827781.USD","LU0965509010.AUD","LU0320765059.SGD","LU0310800379.SGD","LU0109392836.USD","LU2326559502.SGD","LU0048584097.USD","LU0426412945.USD","NQmain","LU1069344957.HKD","LU2404859741.USD","LU2764262908.HKD","LU0965509101.SGD","LU1823568750.SGD","BK4227","LU1974910355.USD","LU1804176565.USD","LU1116320901.HKD","LU0708994859.HKD","BK4585","LU2746668974.SGD","LU1691799644.USD","LU1934455194.USD","LU2264538146.SGD","GB00B4LPDJ14.GBP","LU1228905540.USD","LU2089284900.SGD","LU1267930573.SGD","LU0787776722.HKD","LU1043141123.HKD","LU0868494617.USD","LU0079474960.USD","GB00B4QBRK32.GBP"],"gpt_icon":1},{"id":"2603563759","title":"Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2603563759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603563759?lang=en_us&edition=fundamental","pubTime":"2026-01-14 03:35","pubTimestamp":1768332948,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on XENE stock, giving a Buy rating yesterday. Myles Minter has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-undervalued-pipeline-in-a-drug-story-with-blockbuster-potential-ahead-of-key-2026-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-undervalued-pipeline-in-a-drug-story-with-blockbuster-potential-ahead-of-key-2026-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2603540616","title":"Xenon Pharmaceuticals: Advancing Late-Stage Epilepsy and Depression Programs and Expanding NaV1.7/Kv7 Pipeline Support Buy Rating and $55 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540616","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603540616?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:55","pubTimestamp":1768240522,"startTime":"0","endTime":"0","summary":"Xenon, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-advancing-late-stage-epilepsy-and-depression-programs-and-expanding-nav1-7-kv7-pipeline-support-buy-rating-and-55-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/xenon-pharmaceuticals-advancing-late-stage-epilepsy-and-depression-programs-and-expanding-nav1-7-kv7-pipeline-support-buy-rating-and-55-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","XENE"],"gpt_icon":0},{"id":"2602554295","title":"Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602554295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602554295?lang=en_us&edition=fundamental","pubTime":"2026-01-11 18:30","pubTimestamp":1768127410,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS – Research Report) and Xenon (XENE – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-evolus-eols-and-xenon-xene-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LU0029874061.USD","XENE","BK4588","BK4007","EOLS","BK4137","BK4581","LABU","HCSG","LU0128526141.USD","BK4585","BK4139","XBI"],"gpt_icon":0},{"id":"2602756523","title":"Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602756523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602756523?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:49","pubTimestamp":1767962940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 07:49 ET (12:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0305},{"period":"3month","weight":-0.0333},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1284},{"period":"ytd","weight":-0.0355}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.075368},{"month":4,"riseRate":0.545455,"avgChangeRate":0.022894},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction